Surmodics, Inc. (SRDX) Stock
Surmodics, Inc.
Company profile
Surmodics reported revenue of $126.08 million for fiscal year 2024, down 4.9% from fiscal year 2023. In Q3 2025 (the quarter ended June 30, 2025) revenue was $29.57 million, down 2.6% from a year before. Its largest business segment, Medical Device, brought in 77% of segment revenue in fiscal year 2024; United States was the largest region with 83%. In Q3 2025 it reported a net loss of $5.32 million, against a net loss of $7.55 million a year earlier. Our analysis of its filings shows revenue growing from $99.95 million in fiscal year 2022 to $126.08 million in fiscal year 2024, 12.3% a year on average.
What stands out
- It reported a net loss in each of its last 3 fiscal years, after a profit of $4.24 million in fiscal year 2021; the loss widened from $1.54 million in fiscal year 2023 to $11.54 million in fiscal year 2024.
Figures from company filings; latest fiscal year ended September 30, 2024.
Largest shareholders
- BlackRock Advisors LLC7.71%
- AllianceBernstein LP5.95%
- Vanguard Fiduciary Trust Co.5.67%
- Soleus Capital Management LP5.52%
- Trium Capital LLP5.01%
Share of the company, as of November 8, 2025
In the news
How much revenue does Surmodics make?
Surmodics reported $126.08 million in revenue for fiscal year 2024, down 4.9% from $132.58 million in fiscal year 2023. In Q3 2025 revenue was $29.57 million.
What is Surmodics's largest business segment?
Medical Device, with $97.51 million or 77% of segment revenue in fiscal year 2024. Next: In Vitro Diagnostics (23%).
Where does Surmodics make most of its revenue?
United States: 83% of revenue by region in fiscal year 2024, followed by Foreign (17%).
What companies are similar to Surmodics?
Listed companies of a similar size in the same industry (healthcare equipment manufacturing contractors) include Integer Holdings Corporation (ITGR), Varex Imaging Corporation (VREX), Pro-Dex, Inc. (PDEX), Nutriband Inc. (NTRB).
Has Surmodics made a profit in recent years?
Net income by fiscal year: FY2020, $1.12 million; FY2021, $4.24 million; FY2022, a loss of $27.27 million; FY2023, a loss of $1.54 million; FY2024, a loss of $11.54 million. It reported a net loss in 3 of these 5 years.
Data as of .
How to cite: DataPorium, “Surmodics, Inc. (SRDX)”, data as of Nov 8, 2025, https://dataporium.tech/stocks/SRDX